Subscribe To
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making More than 30 clonoSEQ-related abstracts to be presented at the meeting SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into […] The post Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Uti...
Read More
Content Topics
Adaptive
Biotechnologies
Highlights
Data
Showcasing
Clinical
Utility
Clonoseq
Testing
Patients
Cancers
Annual
Meeting
Forex
Posted: Dec 10 2022, 15:00
Author Name: forextv
Views: 102523